Open access
Impact of PD‐1 Inhibitor Timing Relative to Locoregional Therapy on Outcomes in uHCC Treated With Lenvatinib‐Based Triple Therapy
Jian He
Jian Chen
Bo-Hua Yu
Fu-Qun Wei
Wei-Fu Liu
Pei Huang
Song-Hui Wu
Xiang You
Zhi-Sheng Chen
Zi-Qi Lin
Wu-Hua Guo
Shao-Wu Zhuang
Yi-Ping Chen
Zhong-Wu Chen
Medicine
Abstract
The optimal sequencing of programmed cell death protein 1 (PD‐1) inhibitors relative to locoregional therapy (LRT) in unresectable hepatocellular carcinoma (uHCC) remains undefined. This study evaluated the impact of PD‐1 inhibitor timing on outcomes in patients receiving hepatic arterial infusion chemotherapy (HAIC) or transarterial chemoembolisation (TACE) plus lenvatinib and PD‐1 inhibitors.